Skip to main content
main-content

01.02.2018 | Original Article | Ausgabe 6/2018

Virchows Archiv 6/2018

Extranodal extension of nodal metastases is a poor prognostic moderator in non-small cell lung cancer: a meta-analysis

Zeitschrift:
Virchows Archiv > Ausgabe 6/2018
Autoren:
Claudio Luchini, Nicola Veronese, Alessia Nottegar, Monica Cheng, Takuma Kaneko, Camilla Pilati, Fabrizio Tabbò, Brendon Stubbs, Antonio Pea, Fabio Bagante, Jacopo Demurtas, Matteo Fassan, Maurizio Infante, Liang Cheng, Aldo Scarpa
Wichtige Hinweise

Electronic supplementary material

The online version of this article (https://​doi.​org/​10.​1007/​s00428-018-2309-1) contains supplementary material, which is available to authorized users.
Claudio Luchini and Nicola Veronese contributed equally to this work.

Abstract

Extranodal extension (ENE) of nodal metastasis is defined as the extension of metastatic cells through the nodal capsule into the perinodal tissue. This morphological parameter, recently proposed as an important prognostic factor in different types of malignancy, has not been included in the TNM staging system for non-small cell lung cancer (NSCLC). In this systematic review with meta-analysis, we weighted the prognostic role of ENE in patients with lymph node-positive NSCLC. Two independent authors searched SCOPUS and PubMed through 28 February 2017. Prospective and retrospective studies on NSCLC, comparing patients with presence of ENE (ENE+) ENE+) vs. only intranodal extension (ENE–) and including data regarding prognosis, were considered as eligible. Data were summarized using risk ratios (RR) for the number of deaths/recurrences, and hazard ratios (HR) with 95% confidence intervals (CI) for time-dependent risk related to ENE+, adjusted for potential confounders. We identified 13 studies, including 1709 patients (573 ENE+ and 1136 ENE–) with a median follow-up of 60 months. ENE was associated with a significantly increased risk of mortality of all causes (RR = 1.39, 95% CI: 1.18–1.65, P < 0.0001, I2 = 70%; HR = 1.30, 95% CI: 1.01–1.67, P = 0.04, I2 = 0%) and of disease recurrence (RR = 1.32, 95% CI: 1.04–1.68, P = 0.02, I2 = 42%; HR = 1.93, 95% CI: 1.53–2.44, P < 0.0001, I2 = 0%). We conclude that in NSCLC, requirements for assessment of ENE should be included in gross sampling and ENE status should be included in the pathology report. Inclusion of ENE status in oncology staging systems will allow further assessment of its role as prognostic parameter.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de. Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

Zusatzmaterial
ESM 1 (DOCX 45 kb).
428_2018_2309_MOESM1_ESM.docx
Figure S1 (DOCX 45 kb).
428_2018_2309_MOESM2_ESM.docx
High Resolution Image (TIFF 50 kb).
428_2018_2309_MOESM3_ESM.tif
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 6/2018

Virchows Archiv 6/2018 Zur Ausgabe

Neu im Fachgebiet Pathologie

07.03.2019 | Mammakarzinom | CME | Ausgabe 2/2019

Update der S3-Leitlinie Mammakarzinom

Was gibt es Neues für Pathologen?

21.02.2019 | Schwerpunkt: Neuropathologie | Ausgabe 2/2019

Neuropathologie der Medulloblastome und anderer embryonaler Tumoren des ZNS

Präzisierung der Diagnostik durch Integration genetischer Marker

21.02.2019 | Schwerpunkt: Neuropathologie | Ausgabe 2/2019

Integrierte Diagnostik der diffusen astrozytären und oligodendroglialen Gliome

04.02.2019 | Schwerpunkt: Gynäkopathologie | Ausgabe 1/2019 Open Access

Fallstricke und Probleme bei der Differenzialdiagnose epithelialer Ovarialtumoren